AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization

Molecular Therapy

Volumn 23, Issue 2, 2015, Pages 226-234

  Zhang, Xiaohui ^a   Das, Subrata K ^a   Passi, Samuel F ^a   Uehara, Hironori ^a   Bohner, Austin ^a   Chen, Marcus ^a   Tiem, Michelle ^a   Archer, Bonnie ^a   Ambati, Balamurali K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLT23K PROTEIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ADENO ASSOCIATED VIRUS 2; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOROID; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ELECTRORETINOGRAPHY; GENE EXPRESSION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; REPORTER GENE; RETINAL THICKNESS; SUBRETINAL NEOVASCULARIZATION; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMISTRY; CHOROIDAL NEOVASCULARIZATION; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROTEIN DOMAIN; RETINA; RETINAL PIGMENT EPITHELIUM;

ADENO-ASSOCIATED VIRUS - 2; MURINAE; MUS;

ANIMALS; APOPTOSIS; CHOROID; CHOROIDAL NEOVASCULARIZATION; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENES, REPORTER; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT FUSION PROTEINS; RETINA; RETINAL PIGMENT EPITHELIUM; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84922254959     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.199     Document Type: Article

References (50)

1. la Cour M, Kiilgaard JF and Nissen MH. (2002). Age-related macular degeneration: epidemiology and optimal treatment. Drugs Aging 19: 101-133
2. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT., et al.; Eye Diseases Prevalence Research Group. (2004). Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122: 564-572
3. Friedlander M. (2007). Fibrosis and diseases of the eye. J Clin Invest 117: 576-586
4. Jackson TL and Kirkpatrick L. (2011). Cost comparison of ranibizumab and bevacizumab. BMJ 343: d5058
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M and Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816
6. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR and Zhang K. (2013). Seven-year outcomes in ranibizumab-treated patients in ANCHOR MARINA and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmol 120: 2292-2299
7. Salmon F, Grosios K and Petry H. (2013). Safety profile of recombinant adenoassociated viral vectors: focus on alipogene tiparvovec (Glybera). Expert Rev Clin Pharmacol 7: 53-65
8. Dismuke DJ, Tenenbaum L and Samulski RJ. (2013). Biosafety of recombinant adenoassociated virus vectors. Curr Gene Ther
9. Guziewicz KE, Zangerl B, Komáromy AM, Iwabe S, Chiodo VA, Boye SL., et al. (2013). Recombinant AAV-mediated BEST1 transfer to the retinal pigment epithelium: analysis of serotype-dependent retinal effects. PLoS One 8: e75666
10. Conlon TJ, Deng WT, Erger K, Cossette T, Pang JJ, Ryals R., et al. (2013). Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. Hum Gene Ther Clin Dev 24: 23-28
11. Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Sun J., et al. (2013). Targeting photoreceptors via intravitreal delivery using novel capsid-mutated AAV vectors. PLoS One 8: e62097
12. Cheng Y, Huang L, Li X, Qi, H, Zhou P, Yu, W., et al. (2013). Prevalence of neutralizing factors against adeno-associated virus types 2 in age-related macular degeneration and polypoidal choroidal vasculopathy. Curr Gene Ther 13: 182-188
13. Ju, WK, Kim KY, Duong-Polk KX, Lindsey JD, Ellisman MH and Weinreb RN. (2010). Increased optic atrophy type 1 expression protects retinal ganglion cells in a mouse model of glaucoma. Mol Vis 16: 1331-1342
14. Zhang S, Wu, J, Wu, X, Xu, P, Tian Y, Yi, M., et al. (2012). Enhancement of rAAV2- mediated transgene expression in retina cells in vitro and in vivo by coadministration of low-dose chemotherapeutic drugs. Invest Ophthalmol Vis Sci 53: 2675-2684
15. Cronin T, Chung DC, Yang Y, Nandrot EF and Bennett J. (2012). The Signalling Role of the av5-Integrin Can Impact the Efficacy of AAV in Retinal Gene Therapy. Pharmaceuticals (Basel) 5: 447-459
16. Tarallo V, Bogdanovich S, Hirano Y, Tudisco L, Zentilin L, Giacca M., et al. (2012). Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer. Invest Ophthalmol Vis Sci 53: 7989-7996
17. Igarashi T, Miyake K, Masuda I, Takahashi H and Shimada T. (2010). Adenoassociated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model. Hum Gene Ther 21: 631-637
18. Askou AL, Pournaras JA, Pihlmann M, Svalgaard JD, Arsenijevic Y, Kostic C., et al. (2012). Reduction of choroidal neovascularization in mice by adeno-associated virusdelivered anti-vascular endothelial growth factor short hairpin RNA. J Gene Med 14: 632-641
19. Tuo J, Pang JJ, Cao X, Shen D, Zhang J, Scaria A., et al. (2012). AAV5-mediated sFLT01 gene therapy arrests retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) mice. Neurobiol Aging 33: 433 e1-10
20. Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C., et al. (2011). Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther 19: 326-334
21. Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K., et al. (2013). Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120: 1283-1291
22. Hufnagel RB, Ahmed ZM, Corrêa ZM and Sisk RA. (2012). Gene therapy for Leber congenital amaurosis: advances and future directions. Graefes Arch Clin Exp Ophthalmol 250: 1117-1128
23. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC., et al. (2012). AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4:120ra15
24. Romano MR, Biagioni F, Besozzi G, Carrizzo A, Vecchione C, Fornai F., et al. (2012). Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats. Brain Res 1478: 55-63
25. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K., et al. (2009). CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460: 225-230
26. Nishijima K, Ng, YS, Zhong L, Bradley J, Schubert W, Jo, N., et al. (2007). Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171: 53-67
27. Sayanagi K, Sharma S and Kaiser PK. (2009). Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration. Br J Ophthalmol 93: 622-626
28. Yodoi Y, Tsujikawa A, Nakanishi H, Otani A, Tamura H, Ojima Y., et al. (2009). Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 147: 816-24, 824 e1
29. Leon CS and Leon JA. (1991). Microendoscopic ocular surgery: a new intraoperative diagnostic and therapeutic strategy. Part II: Preliminary results from the study of glaucomatous eyes. J Cataract Refract Surg 17: 573-576
30. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T., et al. (2008). Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One 3: e3554
31. Singh N, Amin S, Richter E, Rashid S, Scoglietti V, Jani PD., et al. (2005). Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 46: 1647-1652
32. Jani PD, Singh N, Jenkins C, Raghava S, Mo, Y, Amin S., et al. (2007). Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 48: 2030-2036
33. Cho YK, Uehara H, Young JR, Tyagi P, Kompella UB, Zhang X., et al. (2012). Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci 53: 2328-2336
34. Luo L, Zhang X, Hirano Y, Tyagi P, Barabás P, Uehara H., et al. (2013). Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano 7: 3264-3275
35. Owen LA, Uehara H, Cahoon J, Huang W, Simonis J and Ambati BK. (2012). Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One 7: e33576
36. Klettner A and Roider J. (2008). Comparison of bevacizumab ranibizumab and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49: 4523-4527
37. Deudero JJ, Caramelo C, Castellanos MC, Neria F, Fernández-Sánchez R, Calabia O., et al. (2008). Induction of hypoxia-inducible factor 1alpha gene expression by vascular endothelial growth factor. J Biol Chem 283: 11435-11444
38. Byeon SH, Lee SC, Choi SH, Lee HK, Lee JH, Chu YK., et al. (2010). Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Invest Ophthalmol Vis Sci 51: 1190-1197
39. Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA., et al.; CATT Research Group. (2014). Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121: 150-161
40. Sarra GM, Stephens C, Schlichtenbrede FC, Bainbridge JW, Thrasher AJ, Luthert PJ., et al. (2002). Kinetics of transgene expression in mouse retina following sub-retinal injection of recombinant adeno-associated virus. Vision Res 42: 541-549
41. Guy J, Qi, X, Koilkonda RD, Arguello T, Chou TH, Ruggeri M., et al. (2009). Efficiency and safety of AAV-mediated gene delivery of the human ND4 complex I subunit in the mouse visual system. Invest Ophthalmol Vis Sci 50: 4205-4214
42. Jacobson SG, Boye SL, Aleman TS, Conlon TJ, Zeiss CJ, Roman AJ., et al. (2006). Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther 17: 845-858
43. Welti J, Loges S, Dimmeler S and Carmeliet P. (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123: 3190-3200
44. Das B, Yeger H, Tsuchida R, Torkin R, Gee MF, Thorner PS., et al. (2005). A hypoxiadriven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxiainducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase ' pathway in neuroblastoma. Cancer Res 65: 7267-7275
45. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K and Linderholm B. (2008). An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 6: 1630-1638
46. Ford KM, Saint-Geniez M, Walshe T, Zahr A and D'Amore PA. (2011). Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci 52: 9478-9487
47. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V., et al. (1998). Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273: 30336-30343
48. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE and D'Amore PA. (2009). An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 106: 18751-18756
49. Singh N, Jani PD, Suthar T, Amin S and Ambati BK. (2006). Flt-1 intraceptor induces the unfolded protein response apoptotic factors and regression of murine injuryinduced corneal neovascularization. Invest Ophthalmol Vis Sci 47: 4787-4793
50. Luo L, Uehara H, Zhang X, Das SK, Olsen T, Holt D., et al. (2013). Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife 2: e00324